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Dysregulated cytokine production contributes to
inflammatory and proliferative diseases. Therefore,
inhibition of proinflammatory mediators such as
TNF, IL-1, and IL-6 is of great clinical relevance.
Actual strategies are aimed at preventing receptor
activation through sequestration of the ligand. Here
we describe the development of an inhibitor of
murine IL-6 based on fused receptor fragments.
Molecular modeling-guided analysis of the murine
IL-6Ra revealed that mutations in the Ig-like domain
D1 severely affect protein function, although D1 is
not directly involved in the ligand-binding interface.
The resulting single chain IL-6 inhibitor (mIL-6-RFP)
consisting of domains D1–D3 of mgp130, a flexible
linker, and domains D1–D3 of mIL-6Ra is a highly
potent and specific IL-6 inhibitor. mIL-6-RFP will
permit further characterization of the role of IL-6 in
various disease models and could ultimately lead to
anti-IL-6 therapy.
INTRODUCTION
Elevated IL-6 levels have been observed in a variety of inflamma-
tory and autoimmune diseases such as rheumatoid arthritis,
Crohn’s disease, and lupus erythematosus (Ishihara and Hirano,
2002). Recently it has been described that besides other cyto-
kines IL-6 plays an important role in the differentiation of Th17
cells (Bettelli et al., 2008). This finding provides a rational expla-
nation for a causative role of IL-6 in autoimmune diseases (Ser-
ada et al., 2008). The proinflammatory activities of IL-6 might act
as a molecular link to inflammation-related cancers (Naugler and
Karin, 2008). Thus, IL-6 has emerged as an important target
molecule in the therapy of human diseases.
The use of soluble receptors is a promising approach for the
generation of highly potent and specific cytokine inhibitors
(Goldenberg, 1999). IL-6 is a pleiotropic cytokine that binds to
a receptor consisting of two subunits: the IL-6-specific non-
signaling receptor subunit IL-6Ra that is found only on
a restricted number of cell types and the ubiquitously expressed
signal-transducing receptor subunit gp130 (Mu¨ller-Newen,Chemistry & Biology2003). Gp130 mediates activation of the Jak/STAT signaling
pathway (Heinrich et al., 2003), which leads to the expression
of well defined STAT3 target genes including the acute phase
proteins, Bcl-2, and VEGF (Sepulveda et al., 2007; Wegenka
et al., 1994; Wei et al., 2003).
Besides the membrane-bound IL-6Ra, a soluble form exists
(sIL-6Ra) that also binds IL-6 and transfers IL-6 responsiveness
to cells lacking membrane-bound IL-6Ra in a process termed
trans-signaling (Scheller et al., 2006). Inhibition of IL-6 by the
use of soluble receptors is challenging because of the agonistic
property of sIL-6Ra. However, complexes of IL-6 and sIL-6Ra
can be neutralized by a soluble form of gp130 (sgp130)
(Mu¨ller-Newen et al., 1998). Both sIL-6Ra and sgp130 are
present in human body fluids. These naturally occurring soluble
receptors are generated by proteolytic processing of
membrane-bound receptors or translation of an alternatively
spliced mRNA (Levine, 2004).
Boulanger et al. (2003) crystallized the IL-6 receptor complex
consisting of human IL-6 bound to soluble fragments of human
IL-6Ra and human gp130. The structure reveals a hexameric
complex with a (IL-6/IL-6Ra/gp130)2 stoichiometry. Receptor
binding occurs through three conserved epitopes of IL-6 (sites
I, II, and III) (Figure 1A). IL-6 binds with its site I to domains 2
and 3 (D2 and D3) of IL-6Ra. D2 and D3 constitute the so called
cytokine binding module (CBM) that dominates this interaction.
Only the heterodimeric complex of IL-6 and IL-6Ra is a substrate
for the engagement of gp130 through site II and III interactions
(Figure 1A). Site II is a composite epitope consisting of contacts
between IL-6 and the domains D2 and D3 of gp130 (site IIa) and
between amino acids of IL-6Ra and gp130 (site IIb). Through
a subsequent interaction involving site III of the cytokine and
the Ig-like domain (D1) of gp130 the high affinity signaling
complex is formed. The site III interaction can also be subdivided
in the interaction between IL-6 and D1 of gp130 (site IIIa) and
IL-6Ra and gp130 (site IIIb) (Boulanger et al., 2003).
We have recently established a fusion protein of the ligand
binding domains of human IL-6Ra (domains D2 and D3) and
human gp130 (domains D1, D2, and D3) that acts as a highly
potent and specific inhibitor for human IL-6 (Ancey et al., 2003;
Metz et al., 2007). Because murine IL-6 does not bind to human
IL-6Ra (Gro¨tzinger et al., 1997) this inhibitor is not suited for an
application in animal models. Therefore, we set out to generate
a receptor fusion protein for the inhibition of murine IL-6 consist-
ing of the respective murine receptor proteins. Interestingly,16, 783–794, July 31, 2009 ª2009 Elsevier Ltd All rights reserved 783
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A Murine IL-6 Inhibitor Based on Fused ReceptorsFigure 1. A Murine IL-6 Receptor Fusion Protein (mIL-6RFPDD1) Built Up in Analogy to the Human IL-6 Receptor Fusion Protein Does Not
Bind IL-6
(A) Assembling of the IL-6 receptor complex according to Boulanger et al. (2003). Interleukin-6 binds the receptor subunits with three conserved sites (sites I, II,
and III). The interaction of site I with the nonsignaling IL-6Ra chain is dominated by domains D2 and D3 of the receptor. The binary IL-6/IL-6Ra complex recruits
gp130 through site IIa and site IIb interactions. Two of these trimeric complexes dimerize via site IIIa and site IIIb interactions, resulting in the formation of the final
hexameric signaling complex.
(B) A murine receptor fusion protein was constructed that lacks D1 of IL-6Ra in accordance with the formerly described human IL-6-RFP (Ancey et al., 2003).
mIL-6RFPDD1 consists of D1–D3 of murine gp130 followed by a 41 amino acid flexible polypeptide linker, domains D2 and D3 of murine IL-6Ra, and a C-terminal
FLAG tag. D2 and D3 of each receptor constitute the respective CBM. Interactions with the sites I, II, and III of IL-6 are indicated by arrows.
(C) IL-6-binding assay. Supernatants (SN) and total cellular lysates (TCL) of COS-7 cells stably transfected with an expression vector encoding mIL-6RFPDD1 were
subjected to precipitation with IL-6-Sepharose or immunoprecipitation with a FLAG antibody. Precipitated proteins were analyzed by western blot analysis using
the FLAG antibody.a murine receptor fusion protein constructed in analogy to the
human receptor fusion protein does not bind IL-6. By molecular
modeling-guided mutagenesis we found that the Ig-like domain
(D1) of the murine IL-6Ra is required for receptor surface expres-
sion and IL-6 binding. Based on these findings we present a novel
receptor fusion protein consisting of domains D1, D2, and D3 of
murine IL-6Ra fused to domains D1, D2, and D3 of murine
gp130. This fusion protein acts as a highly potent inhibitor for
murine, rat, and human IL-6.
RESULTS
A Murine IL-6-RFP Lacking the Ig-like Domain D1
of mIL-6Ra Does Not Bind IL-6
In the present study we aimed at generating a potent and cyto-
kine-specific inhibitor of murine IL-6 in analogy to our previously
described fusion protein approach for the inhibition of human
IL-6 (Ancey et al., 2003). According to the composition of the
human receptor fusion protein hIL-6-RFP, we first generated
a fusion protein consisting of domains D1, D2, and D3 of murine
gp130 (comprising the Ig-like domain and the CBM) and
domains D2 and D3 of murine IL-6Ra (comprising the CBM).
The receptor domains were fused using a polypeptide linker of
41 amino acids and a C-terminal FLAG tag was added for detec-
tion purposes (Figure 1B). According to this concept, domain D1
of IL-6Ra was not included in the fusion protein (mIL-6-RFPDD1).784 Chemistry & Biology 16, 783–794, July 31, 2009 ª2009 ElsevieWe previously showed that the corresponding human receptor
fusion protein hIL-6-RFP binds IL-6 with high affinity and inhibits
IL-6 responses (Metz et al., 2007). For a first functional investiga-
tion, mIL-6-RFPDD1 was stably expressed in COS-7 cells. Super-
natants of cells were collected and cellular lysates were
prepared. Ligand binding of mIL-6-RFPDD1 was analyzed by
precipitation with immobilized IL-6. In parallel, the fusion protein
was precipitated both from supernatant and cellular lysates with
a FLAG antibody to prove expression of the recombinant protein.
Figure 1C shows that the murine receptor fusion protein mIL-6-
RFPDD1 lacking domain D1 of mIL-6Ra does not bind to immobi-
lized IL-6 although it is present in both supernatant and lysate.
Accordingly, mIL-6RFPDD1 does not inhibit IL-6 bioactivity
(data not shown).
Structural Comparison of Murine and Human IL-6Ra
In order to investigate whether different structural requirements
for IL-6 binding by murine and human IL-6-RFP may contribute
to the loss of ligand-binding capacity, we generated model
structures of murine gp130 and murine IL-6Ra based on the
solved crystal structures of the human proteins (Boulanger
et al., 2003; Varghese et al., 2002). The most striking differences
were observed for IL-6Ra. Figure 2A shows a section of the
alignment of IL-6Ra sequences of different origin and illustrates
the high degree of homology between different species. The
most prominent differences between the solved crystal structurer Ltd All rights reserved
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become apparent in the overlay of hIL-6Ra (red ribbon) and
mIL-6Ra (green ribbon) represented in Figure 2B. These pre-
dicted structural differences are located in the region preceding
domain D1 (preD1 region) as well as in domains D1 and D2. The
preD1 region is part of a remarkable structural feature of the
IL-6Ra: it folds back to domain D2, where it is covalently fixed
by a disulfide bond between Cys6 in the preD1 region and
Cys174 in D2 (Cys171 in the murine receptor) resulting in
a precise positioning of the N-terminal amino acids. Strikingly,
the N-terminal amino acids and the region within domain D2
that is contacted by these amino acids differ in the human and
murine proteins. The presence of larger hydrophobic amino
acid side chains for the residues at the positions 2 and 3 in
murine IL-6Ra (Val2 and Leu3, Figures 2A and 2C [1]) could indi-
cate a stronger interaction with the surrounding amino acids of
domain D2. In this region domain D2 of the murine receptor is
characterized by an extension of the region encompassing the
Figure 2. Structural Analysis of Murine
IL-6Ra
(A) Sections (preD1 region, parts of D1 and D2) of
the sequence alignment of IL-6Ra from different
species. Highly conserved residues are depicted
in red. The hydrophobic Val-Leu and Ala-Pro
motifs conserved in some of the species are repre-
sented in blue and green, respectively. Cysteine
residues involved in the disulfide bond involving
Cys6 are highlighted in yellow. Secondary struc-
ture elements for human IL-6Ra (Varghese et al.,
2002) as well as amino acid numbers for human
and murine IL-6Ra are given.
(B) Overlay of the ribbon representations of the
solved structure (Varghese et al., 2002) of human
IL-6Ra (red ribbon, domains D1 to D3; Brookhaven
data bank entry code 1N26) and our model struc-
ture of the corresponding domains of murine
IL-6Ra (green ribbon). The disulfide bond involving
Cys6 and Cys174 (human IL-6Ra) is represented
as a stick model. The program PyMOL was used
for representation of the structures.
(C) Schematic representation of the generated
mutants of murine IL-6Ra. Some of the b strands
in domains D1 and D2 are indicated by arrows.
The amino acids of the preD1 region as well as
the disulfide bridge are shown. Point mutations
are highlighted in red.
strands bD and bC as well as the con-
necting loop L2. In the human system,
this loop contributes to IL-6 binding,
although to a lesser extent than the loops
L3 and L5 located in domains D2 and D3,
respectively. It is thus conceivable that
the hydrophobic N-terminal amino acids
of the preD1 region contribute to IL-6
binding by orienting or stabilizing the
region around the beta strands bD and
bC in domain D2.
Based on this structural analysis we
investigated the contribution of N-
terminal amino acids and the disulfide
bond to receptor function. For this purpose we generated several
point and deletion mutants of the murine IL-6Ra. An IL-6Ra
construct lacking both the preD1 region as well as domain D1
(mIL-6RDD1; Figure 2C [2]) was generated in order to verify the
results shown in Figure 1C. Furthermore, the first 11 amino acids
of the preD1 region were deleted to study its potential impor-
tance for IL-6 binding (mIL-6RDpreD1; Figure 2C [3]). In order to
evaluate the importance of the cysteine bridge between the
preD1 region and domain D2, we mutated Cys6 to Ser to prevent
the formation of the disulfide bond (mIL-6RC6S; Figure 2C [4]). To
assess the importance of the N-terminal part of the preD1 region,
the first three amino acids (Leu1, Val2, and Leu3) were replaced
by a Ser-Gly-Ser motif (mIL-6RSGS; Figure 2C [5]). Finally, the
core domain D1 was deleted by connecting the preD1 region
to domain D2 (mIL-6RpreD1DD1; Figure 2C [6]). As can be seen
in Figure 2B, the C terminus of the preD1 region is in close prox-
imity to the N terminus of domain D2 so that the two regions can
easily be linked.Chemistry & Biology 16, 783–794, July 31, 2009 ª2009 Elsevier Ltd All rights reserved 785
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of the Murine IL-6 Receptor a Subunit
Murine IL-6 does not bind to human IL-6Ra (Gro¨tzinger et al.,
1997). Therefore, the human HepG2 cell line was used to study
the murine IL-6Ra mutants without background of endogenous
receptors. HepG2 cells were stably transfected with expression
vectors encoding wild-type and mutant murine IL-6Ra tagged
with the yellow fluorescent protein (YFP) at their C termini. Cell
surface expression of the receptor proteins was analyzed by
flow cytometry (Figure 3A). Only wild-type and the SGS mutant
are expressed at the cell surface, all the other mutants were
not detectable. This finding was corroborated by confocal
laser-scanning microscopy of living cells (Figure 3B). Only mIL-
6Ra wild-type and the SGS mutant colocalizes with the trypan
blue staining that marks the plasma membrane. The other
mutants remain in intracellular reticular structures. Thus, domain
D1 and the disulfide bond between the preD1 region and D2 are
required for cell surface expression of mIL-6Ra. The preD1
region in the absence of D1 is not sufficient to warrant cell
surface expression (Figure 3, last panels).
Next we investigated whether the SGS mutation at the N
terminus of mIL-6Ra interferes with the bioactivity of the
receptor in terms of IL-6-mediated receptor activation. DNA
binding of activated STATs and induction of a STAT3-specific
reporter gene were analyzed. HepG2 cells stably transfected
with IL-6Ra wild-type or the SGS mutant were first analyzed
by flow cytometry (Figure 4A) before they were used for the
experiments depicted in Figures 4B and 4C. Quantitative anal-
ysis of the flow cytometry data revealed a somewhat higher
cell surface expression of the SGS mutant compared to wild-
type protein. These cells were stimulated for a short time
period (20 min) with different concentrations of mIL-6 (25 pg/
ml up to 2.5 ng/ml). Nuclear extracts were prepared and
DNA-bound STAT proteins were analyzed by electrophoretic
mobility shift assay (EMSA). Equal amounts of nuclear protein
of both cell lines were incubated with a P32-labeled oligonucle-
otide containing a STAT binding site. The upper part of Fig-
ure 4B shows shifted bands of DNA-bound STAT1 and STAT3
species from both cell lines. STAT3 homodimers represent the
most prominent dimer species after mIL-6 stimulation. The cor-
responding band is weaker in cells expressing the SGS mutant
compared to wild-type protein. Similarly, the proportion of
STAT1/3 heterodimers and STAT1/1 homodimers, which pref-
erentially form at higher cytokine concentrations, differs
considerably between wild-type receptor and mutant as is
evident from the quantitative evaluation of the autoradiography
(diagrams in Figure 4B).
To further determine the biological relevance of the distinct
differences in the activation patterns for both receptors, tran-
scriptional activity of activated STAT proteins was analyzed in
both cell lines. Cells were transfected with a STAT3-inducible
reporter gene construct containing the rat a2M promoter and a
control plasmid. Cells were stimulated with mIL-6 (2.5, 5, and
10 ng/ml) for 18 hr and luciferase activity was measured.
Figure 4C shows a considerably reduced reporter gene induction
in cells expressing the SGS mutant compared to wild-type. The
effect is most prominent at low cytokine concentrations. Taken
together, the mutation of N-terminal amino acids diminishes
the bioactivity of the murine IL-6Ra.786 Chemistry & Biology 16, 783–794, July 31, 2009 ª2009 ElsevierA Murine IL-6 Receptor Fusion Protein Comprising D1
of IL-6Ra (mIL-6-RFP) Binds IL-6
All of the mIL-6Ra mutants lacking the N-terminal Ig-like domain
D1 or at least the disulfide bond between the preD1 region and
D2 were not expressed at the cell surface and thus not acces-
sible for functional binding assays. Therefore, we decided to
analyze IL-6 binding of these mutants in the context of a receptor
fusion protein with domains D1–D3 of murine gp130. All receptor
fusion proteins were equipped with a V5 epitope tag at their C
termini and stably expressed in HEK293 cells. Figure 5 shows
the analysis of protein expression in cellular lysates and superna-
tants by precipitation with a V5 antibody. Ligand binding was
analyzed by precipitation with immobilized IL-6. Again, all the
mutants lacking domain D1 or the disulfide bond between the
preD1 region and D2 of mIL-6Ra were weakly expressed, indi-
cating a prominent role of these structural features for process-
ing, folding, and secretion of the protein. Most interestingly, the
expressed mutants are not precipitated with immobilized IL-6,
indicating impaired ligand binding (Figure 5, lanes 2, 14, 18,
and 22).
The fusion protein derived from mIL-6Ra wild-type is most
strongly expressed. In the cellular lysate (Figure 5, lane 11),
besides the mature form that corresponds to the band in the
supernatant (Figure 5, lane 12), a non-terminally processed
form of lower molecular mass is visible. Both forms are precipi-
tated with IL-6-Sepharose (Figure 5, lanes 9 and 10), indicating
that glycosylation of the fusion protein is not required for ligand
binding. Comparison of the precipitation of the fusion proteins
derived from mIL-6Ra wild-type and the SGS mutant reveals
that the SGS mutation leads to a decrease in IL-6 binding
(Figure 5, compare lanes 6, 8, 10, and 12). This finding is in line
with the reduced bioactivity of the SGS mutant (Figure 4). The
fusion protein consisting of D1, D2, and D3 of mgp130 and D1
(including the preD1 domain), D2, and D3 of mIL-6Ra termed
mIL-6-RFP was further characterized.
The complex of mIL-6-RFP and IL-6 was analyzed by blue
native PAGE. The native gel loaded with different amounts of
mIL-6-RFP and YFP-hIL-6 was scanned with a fluorescence
scanner. The complex of YFP-hIL-6 (50 kDa) and mIL-6-RFP
(100 kDa) has an apparent molecular mass of 600 kDa
(Figure 5B, left panel) that corresponds to four molecules of
each of YFP-hIL-6 and mIL-6-RFP in the complex. To verify
this observation a similar experiment was performed with mIL-
6 (20 kDa). This protein is non-fluorescent and therefore was de-
tected by western blotting (Figure 5B, right panel). The apparent
molecular mass of the complex corresponds to about 500 kDa,
again arguing for a complex of (mIL-6)4(mIL-6-RFP)4 stoichiom-
etry. Non-bound IL-6 is not detectable in the native gel or
western blot due to its low molecular mass.
mIL-6-RFP Is a Potent Inhibitor for Murine,
Rat, and Human IL-6
Human IL-6 acts on human, murine, and rat cells, whereas murine
IL-6 only acts on cells expressing murine IL-6Ra. We therefore
tested whether mIL-6-RFP is able to inhibit IL-6 of different
species. Human HepG2 hepatoma, murine B9 hybridoma, and
rat Fao hepatoma cells were stimulated for 20 min with human,
murine, and rat IL-6, respectively, in the presence of superna-
tants from HEK293 cells stably expressing mIL-6-RFP or controlLtd All rights reserved
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the fusion protein was determined by ELISA. Cellular lysates
were prepared and tyrosine phosphorylation of STAT3 was
analyzed by western blotting. Equal loading was verified by stain-
ing of total STAT3. Figure 6A shows that mIL-6-RFP inhibits the
bioactivity of IL-6 from all three species with comparable efficacy.
Next the cytokine-specificity of mIL-6-RFP was analyzed.
IL-11, OSM, and CNTF, which share the signal transducing
Figure 3. Subcellular Localization of IL-6Ra Mutants
(A) HepG2 cells were stably transfected with the mutants of murine IL-6Ra (Figure 2C) fused to YFP at their C termini. Cell surface expression was analyzed by flow
cytometry using an mIL-6Ra antibody and a phycoerythrin-conjugated secondary antibody (red histograms). The isotype controls are shown as blue histograms.
(B) Living HepG2 cells stably transfected with the IL-6Ra-YFP constructs were analyzed by confocal microscopy. The membrane was stained with trypan blue.
YFP fluorescence is shown in yellow, trypan blue fluorescence in red. Scale bars represent 10 mm.Chemistry & Biology 16, 783–794, July 31, 2009 ª2009 Elsevier Ltd All rights reserved 787
Chemistry & Biology
A Murine IL-6 Inhibitor Based on Fused Receptorsreceptor subunit gp130, belong to the cytokines most closely
related to IL-6. HepG2 cells were stimulated with IL-6, IL-11,
and OSM for 20 min in the presence of supernatants containing
mIL-6-RFP. Subsequently, cellular lysates were prepared and
analyzed for tyrosine phosphorylation of STAT3 by western
blot analysis. Figure 6B shows that mIL-6-RFP inhibits IL-6 but
not IL-11 and OSM. An about 10-fold surplus of mIL-6-RFP
over IL-6 is sufficient to reduce STAT3 phosphorylation to back-
ground levels. The same surplus does not inhibit IL-11 activity.
Remarkably, even a 110-fold molar surplus of mIL-6-RFP over
OSM does not lead to a reduction of STAT3 phosphorylation.
IL-6-mediated biological effects can be transmitted by both
membrane-bound and soluble IL-6Ra. The latter process has
been termed trans-signaling. The role of trans-signaling in
disease progression is considerable because in the presence
Figure 4. Activity of the SGS Mutant
Compared to IL-6RaWild-Type
(A) HepG2 cells expressing mIL-6Ra-YFP wild-
type or the mIL-6RaSGS-YFP mutant were
analyzed by flow cytometry for receptor surface
expression as described in Figure 3A. The portion
of highly fluorescent cells beyond the marker M1 is
indicated in the histograms.
(B) After FACS analysis the stably transfected
HepG2 cells were stimulated with different
amounts of mIL-6 for 20 min as indicated. Nuclear
extracts were prepared and incubated with a [32P]-
labeled SIEm67 probe (Wagner et al., 1990). STAT
DNA binding was analyzed by an EMSA. DNA-
bound STAT species were visualized by autoradi-
ography. All samples were run on the same gel.
The radioactivity was quantified with a Phos-
phoImager. The intensities of the STAT bands
were normalized with the intensities of the nonspe-
cific bands at the bottom of the gel. The values are
depicted as bar charts.
(C) Stably transfected HepG2 cells were tran-
siently transfected with a reporter gene plasmid
encoding firefly luciferase under control of an
IL-6-responsive a2M promoter and a constitutively
active promotor construct encoding renilla lucif-
erase. Twelve hours after transfection cells were
stimulated for 16 hr with mIL-6 at different concen-
trations as indicated. Subsequently cells were
lysed and luciferase activities were measured.
The diagrams show the normalized reporter gene
induction from cells transfected with IL-6Ra wild-
type or the SGS mutant. The percent reduction
of the response evoked by the SGS mutant
compared to the wild-type response is indicated.
Standard deviations are shown for a triplicate
experiment.
of soluble IL-6Ra cell populations lacking
membrane-bound IL-6Ra gain respon-
siveness to IL-6 (Scheller et al., 2006).
The effect of mIL-6-RFP on IL-6 trans-
signaling and on CNTF activity was
analyzed on HEK293 cells that express
only low amounts of membrane-bound
IL-6Ra (Figure 6C). STAT3 phosphoryla-
tion in response to IL-6/sIL-6Ra stimula-
tion is completely blocked in the presence of mIL-6-RFP.
CNTF-induced STAT3 phosphorylation is unaffected. Similar
observations were made with SH-SY5Y neuroblastoma cells
(data not shown). mIL-6-RFP not only acts on established cell
lines but also on primary cells as is shown by the inhibition of
IL-6 activity on primary rat hepatocytes (Figure 6D). Thus, mIL-
6-RFP is a highly potent and cytokine-specific inhibitor of IL-6
signaling through membrane-bound and soluble IL-6Ra that
exhibits cross-reactivity for human, murine, and rat IL-6.
Comparison of mIL-6-RFP with an IL-6-Neutralizing
Monoclonal Antibody
Neutralizing antibodies against a cytokine or its receptor are
often used to block cytokine activity. In the following experiment,
we compared the inhibitory activities of mIL-6-RFP and a well788 Chemistry & Biology 16, 783–794, July 31, 2009 ª2009 Elsevier Ltd All rights reserved
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A Murine IL-6 Inhibitor Based on Fused ReceptorsFigure 5. IL-6 Binding of mIL-6Ra Mutants in the Context of a Receptor Fusion Protein
(A) All mIL-6Ra mutants were stably expressed as receptor fusion proteins with a C-terminal V5 epitope tag in HEK293 cells. Fusion proteins were precipitated
from cellular lysates (CL) or cell supernatants (SN) by either IL-6 Sepharose or a V5 epitope antibody. Precipitates were analyzed by western blotting using the V5
epitope antibody.
(B) YFP-hIL-6 or mIL-6 were incubated with mIL-6-RFP for 30 min at room temperature. Protein complexes formed were analyzed by native polyacrylamide gel
electrophoresis (4%–16% polyacrylamide gradient). The gel loaded with YFP-hIL-6 was analyzed with a Typhoon fluorescence scanner (left panel) the gel loaded
with mIL-6 was analyzed by western blotting using the mIL-6 antibody mab406.characterized IL-6-neutralizing antibody, mab406 (LaSpina
et al., 2008), on the IL-6-induced proliferation of murine B9 cells.
B9 cells were stimulated with a constant amount of IL-6 in the
presence of varying concentrations of mIL-6-RFP (Figure 7A)
or the IL-6-neutralizing antibody mab406 (Figure 7B). The IC50
for both mIL-6-RFP (apparent molecular mass of 100 kDa) and
mab406 (150 kDa) is about 4 ng/ml, corresponding to 40 and
27 pM, respectively. Thus, the inhibitory activity of mIL-6-RFP
is comparable with an established IL-6-neutralizing antibody.
DISCUSSION
Soluble receptors have been established as highly specific and
potent inhibitors of cytokine action. In first approaches, inhibition
of cytokines that signal through homooligomeric receptors has
been achieved by dimerization of the corresponding soluble
receptors through a Fc tag. The best studied example is the
TNF inhibitor Etanercept, a soluble TNFR-Fc fusion protein
(Goldenberg, 1999). However, most cytokines signal through
heteromeric receptors consisting of two different receptor
subunits. In such cases, the inhibitor should contain portions of
both receptors to achieve high affinity binding. Inhibitors for
IL-1, IL-4, and IL-6 have been generated by fusion of the corre-
sponding soluble receptor proteins to an Fc tag. However, after
protein expression, the desired heterodimers have to be sepa-
rated from the homodimeric byproducts (Economides et al.,
2003). We developed another approach based on the inline
fusion of cytokine receptors. To limit the size of the resulting
receptor fusion protein only the domains of the receptors thatChemistry & Biology 16are involved in ligand binding were integrated in the construct.
Based on this strategy we generated the fusion protein hIL-6-
RFP, consisting of domains D1–D3 of human gp130, a flexible
peptide linker, and domains D2 and D3 of human IL-6Ra. (Ancey
et al., 2003; Metz et al., 2007), and recently a receptor fusion
protein for the inhibition of leukemia inhibitory factor (Metz
et al., 2008).
For the inhibition of IL-6 in murine disease models, a potent
and specific inhibitor for murine IL-6 is highly desirable.
However, murine IL-6 does not bind to human IL-6Ra and hence
not to hIL-6-RFP. Therefore, we intended to generate a fusion
protein consisting of the murine receptor proteins. We found
that a murine receptor fusion protein built up in analogy to hIL-
6-RFP is not active (Figure 1C) although the main epitopes
involved in ligand binding are present. An inspection of the struc-
tures of gp130 and IL-6Ra based on the solved structures of the
human proteins (Boulanger et al., 2003; Varghese et al., 2002)
and molecular models of the murine proteins pointed to a differ-
ential role of the Ig-like domain in IL-6Ra function. The main
differences were found in the preD1 region, a stretch of 14 amino
acids preceding domain D1 that folds back to domain D2, and
the corresponding region in D2 that interacts with the preD1
region (Figures 2A and 2B). According to the model, the preD1
region might play a role in positioning of the exposed bC-bD
loop (loop L2) of D2 that takes part in ligand binding.
The intramolecular interaction of the preD1 region and D2
involves a disulfide bond between Cys6 in the preD1 region
and a cysteine residue in D2 (Cys174 in hIL-6Ra corresponding
to Cys171 in mIL-6Ra) that is conserved. Mutants of mIL-6Ra, 783–794, July 31, 2009 ª2009 Elsevier Ltd All rights reserved 789
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RFP
(A) Concentrated supernatants from HEK293 cells
containing 190 ng/ml mIL-6-RFP or concentrated
supernatants from mock transfected cells were
preincubated for 30 min with the indicated concen-
trations of human, murine, or rat IL-6 resulting in
a 12-, 6-, or 3-fold molar surplus of mIL-6-RFP.
The indicated human, murine, and rat cells were
stimulated for 20 min. Cellular lysates were
analyzed by western blotting. After detection of
phosphorylated STAT3 a counterstaining against
STAT3 was performed as a loading control.
(B) Concentrated supernatants from stably trans-
fected HEK293 cells containing 190 ng/ml mIL-6-
RFP were preincubated with IL-6, IL-11, or OSM
at the indicated concentrations for 30 min.
HepG2 cells were stimulated for 20 min and cellular
lysates were analyzed as described in (A).
(C) Concentrated supernatants from stably trans-
fected HEK293 cells containing 190 ng/ml mIL-
6-RFP were preincubated with CNTF or IL-6 (in
the presence of 0.5 mg/ml sIL-6Ra) at the indi-
cated concentrations for 30 min. HEK293 cells
were stimulated for 20 min and cellular lysates
were analyzed as described in (A).
(D) Murine IL-6 at the indicated concentrations was
preincubated with supernatants of HEK293 cells
containing 190 ng/ml mIL-6-RFP or an equivalent
amount of control supernatant for 30 min. Primary
rat hepatocytes were stimulated for 20 min and
cellular lysates were analyzed as described in (A).in which this disulfide bond is destroyed (DD1,DpreD1, and C6S;
Figure 2C) are not expressed on the cell surface (Figure 3). In the
context of a receptor fusion protein, these mutants are only
weakly expressed and devoid of ligand binding activity
(Figure 5A). Thus, the disulfide bond is important for protein
secretion and receptor function probably by affecting the tertiary
structure of D2. Positioning of the preD1 region in front of D2 is
not sufficient to restore receptor function, arguing for a syner-
gistic role of D1 and the preD1 region for disulfide bond forma-
tion and folding of the domain D2. Deletion of D1, including the
preD1 region in the human IL-6Ra, also leads to defective cell
surface expression. However, ligand binding is not affected
(Vollmer et al., 1999). Therefore, in the context of hIL-6-RFP D2
and D3 of hIL-6Ra are sufficient (Ancey et al., 2003).
Two N-terminal sequence motifs are conserved in IL-6Ra
proteins from different species. The hydrophobic LVL motif
found in mice, rat, and cattle is replaced by LAP in other species
including humans. The larger hydrophobic amino acids of the
LVL motif could be involved in a more extensive hydrophobic
interaction with D2 that might also be important for positioning
of the loop L2. Indeed, replacement of these amino acids by
smaller and more hydrophilic residues (SGS mutant; Figure 2C)
resulted in a receptor that is less sensitive to stimulation by
IL-6 (Figure 4). In the context of the receptor fusion protein, the
SGS mutation affects ligand binding (Figure 5A). Thus, the LVL
motif might play the proposed role in proper orientation of the
L2 loop for IL-6 binding. Even a contribution of the first leucine
residue in the site IIIb contact with gp130 is conceivable from
the model.790 Chemistry & Biology 16, 783–794, July 31, 2009 ª2009 ElsevierBased on the above structural considerations and the corre-
sponding experimental data, a murine IL-6 receptor fusion
protein, mIL-6-RFP, was designed that consists of D1–D3 of
murine gp130, a flexible linker, and D1–D3 of murine IL-6Ra
including the preD1 region. The molecular mass of the IL-6/IL-
6-RFP complex was determined by native gel electrophoresis
(Figure 5B). The estimated molecular masses fit to a complex
of (IL-6)4(mIL-6-RFP)4 stoichiometry. According to the X-ray
structure of the IL-6 receptor complex (Boulanger et al., 2003),
an (IL-6)2(mIL-6-RFP)2 stoichiometry would have been expected
as has been observed for the human IL-6/hIL-6-RFP complex
(Metz et al., 2007). The higher order complex formation might
be attributed to D1 of IL-6Ra, which is lacking in hIL-6-RFP
and in the soluble IL-6Ra used for X-ray crystallography. Higher
order receptor complex formation has recently been described
for the GM-CSF receptor complex (Hansen et al., 2008).
mIL-6-RFP is a potent inhibitor of murine and rat IL-6. mIL-6-
RFP acts through sequestration of the ligand since no IL-6-
dependent incorporation of mIL-6-RFP in membrane-bound
receptor complexes was detectable (data not shown). It is
known that human IL-6 binds to the murine receptors (Gro¨tzinger
et al., 1997). Therefore, mIL-6-RFP is also suited for the inhibition
of human IL-6 (Figure 6A). Regarding receptor composition,
IL-11 is most closely related to IL-6. IL-11 first binds to IL-11Ra
that has a similar domain structure as IL-6Ra. Analogous to IL-6,
the complex of IL-11 and IL-11Ra signals through a gp130 ho-
modimer (Hilton et al., 1994). OSM signals through a heterodimer
of gp130 and the OSM receptor. It has been shown that OSM
binds with low affinity to gp130 alone (Staunton et al., 1998).Ltd All rights reserved
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6 the fusion protein mIL-6-RFP does not affect the bioactivity of
IL-11 and OSM despite the fact that these cytokines share the
cytokine receptor gp130 with IL-6 (Figure 6B). As human CNTF
was reported to bind to human IL-6Ra (Schuster et al., 2003),
we tested whether mIL-6-RFP would inhibit CNTF-mediated
Figure 7. Comparison of the IL-6 Inhibitory Activity of mIL-6-RFP
and a Neutralizing IL-6 Antibody
(A and B) B9 cells were incubated with a constant amount of mIL-6 (10 pg/ml) in
the presence of mIL-6-RFP or the neutralizing IL-6 antibody (mab406) at
different concentrations (serial 2-fold dilutions). After 72 hr of incubation, viable
cells were quantified using the colorimetric XTT assay. Mean values from three
independent experiments are shown with standard deviations.Chemistry & Biology 16signaling. However, rat CNTF is not blocked by mIL-6-RFP
(Figure 6C), indicating that in rat and murine systems mIL-6-
RFP is a specific IL-6 inhibitor.
The complex of IL-6 and soluble IL-6Ra (sIL-6Ra) acts on cells
that express gp130 but lack the membrane-bound IL-6Ra. This
phenomenon is relevant in certain inflammatory conditions,
where IL-6Ra is shed from infiltrating leukocytes by limited
proteolysis and sensitizes other cells such as endothelial cells
or fibroblast for IL-6 (Scheller et al., 2006). mIL-6-RFP contains
the domains D1–D3 of gp130, which are sufficient for binding
of IL-6/sIL-6Ra complexes (Horsten et al., 1995). Indeed, mIL-
6-RFP blocks IL-6/sIL-6Ra (Figure 6C) irrespective of whether
IL-6 and sIL-6Ra have been preincubated or all compounds
were added simultaneously (data not shown). Thus, mIL-6-RFP
can be regarded as a pan-IL-6 inhibitor that blocks classical as
well as trans-signaling.
We found that the inhibitory activity of mIL-6-RFP is compa-
rable to the widely used IL-6-neutralizing monoclonal antibody
mab406. If one takes into account that the antibody has two
IL-6-binding sites while the fusion protein binds only one IL-6
molecule, the activity per binding site is higher for mIL-6-RFP
compared to the antibody. The use of neutralizing monoclonal
antibodies in the treatment of IL-6-dependent diseases have
been disappointing due to the long half-life of IL-6/antibody
complexes (Lu et al., 1992). The accumulation of immune
complexes is mediated mainly by the Fc part of the antibody
(Vaccaro et al., 2005). Since mIL-6-RFP lacks an Fc fragment it
might exhibit more favorable pharmacokinetics that lead to elim-
ination of bound IL-6. Conversely, through the fusion of appro-
priate protein fragments that increase or diminish the half-life
of mIL-6-RFP, the pharmacokinetics might be properly adjusted.
SIGNIFICANCE
In this study we presented the development of a new inhib-
itor for IL-6, mIL-6-RFP, that was guided by mutagenesis
based on a molecular model of mIL-6Ra. In the case of the
human receptor fusion protein, the domains directly
involved in ligand binding were sufficient. However, for the
murine receptor fusion protein, the domain (D1) of mIL-6Ra
had to be considered, which is important for the stabilization
and adjustment of the neighboring ligand-binding domains
(D2 and D3). Thus, for each potential receptor fusion protein
the optimal compromise between protein size and structural
requirements for function has to be worked out by experi-
mental investigations. The concept of inline fusion of the
receptors has the great advantage that the inhibitor is en-
coded by a single gene, compared to antibodies or cytokine
traps where two subunits have to be expressed in parallel.
This strategy offers numerous possibilities for specific cyto-
kine inhibition in gene delivery approaches based on viral
vectors, transgenic animals, and, finally, gene therapy.
EXPERIMENTAL PROCEDURES
Cytokines and Cytokine Receptors
Recombinant human IL-6 for coupling to CNBr-Sepharose 4B (GE Healthcare)
was prepared as described by Arcone et al. (1991). Cytokines used for exper-
iments with cell cultures were purchased from R&D Systems (human and rat, 783–794, July 31, 2009 ª2009 Elsevier Ltd All rights reserved 791
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OSM). Soluble human IL-6Ra was prepared as described by Weiergra¨ber
et al. (1995). His-tagged YFP-IL-6 was expressed in E. coli (BL21DE3pLys)
and purified by nickel-chelate chromatography on Ni-NTA columns (QIAGEN).
Cell Culture and Transfection of Cells
B9 murine hybridoma cells (DSMZ ACC221) were cultured in RPMI640
(GIBCO) supplemented with 10% FCS (CytoGen) and 50 mM b-mercaptoetha-
nol in the presence of 10–100 pg/ml human IL-6. COS-7 cells (DSMZ ACC60),
HEK293 human embryonic kidney cells (DSMZ ACC 305), and FaO rat hepa-
toma cells (ECACC 89042701) were grown in DMEM (GIBCO) with 10%
FCS. HepG2 human hepatoma cells (ATCC HB-8065) were grown in DMEM/
F12 (GIBCO) with 10% FCS. Primary rat hepatocytes were prepared as
described (Fehrenbach et al., 2001). All cells were cultivated at 37C in a
water-saturated atmosphere containing 5% CO2. The DEAE-Dextran method
and Lipofectamine were used for the transfection of COS-7 cells. HEK293 and
HepG2 cells were transfected with Fugene6 (Roche) or Lipofectamine2000
(Invitrogen). Stable transfectants were selected with the antibiotic geneticin
(Sigma-Aldrich).
Expression Vectors
The murine IL-6Ra and murine gp130 cDNAs were amplified by RT-PCR using
RNA prepared from murine RAW 264.7 macrophages as a template. All
expression vectors were constructed using the pcDNA3.1(+) plasmid (Invitro-
gen). The various constructs encoding the IL-6Ra mutants (Figure 2C) in the
context of membrane-bound IL-6Ra-YFP fusion proteins or soluble IL-6
receptor fusion proteins were generated according to standard procedures.
The murine IL-6 receptor fusion protein mIL-6-RFP consists of a signal
sequence derived from preprotrypsin followed by domains D1, D2, and D3
of mature murine gp130 (up to amino acid arg323), a flexible Ala-Gly-Ser-
rich linker of 41 amino acids (Ancey et al., 2003), domains D1, D2, and D3 of
mature murine IL-6Ra (up to thr300), and finally a combination of V5 epitope
and hexa-histidine tag (V5his tag) for detection.
ELISA
Concentrations of mIL-6-RFP were determined by a sandwich ELISA. A vali-
dated antibody combination directed against domains D1–D3 of the mIL-6Ra
wasused (R&DSystems). Soluble mIL-6Ra (R&D Systems)served asa standard.
Immunoprecipitation, Western Blot, and Native Gels
Recombinant proteins were precipitated either from cell supernatants or
lysates of stably transfected cells. Cells in suspension were lysed with radioim-
munoprecipitation assay lysis buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl,
1 mM EDTA, 0.5% Nonidet P-40, 1 mM NaF, 15% glycerol, 1 mM Na3VO4,
1 mM phenylmethylsulfonyl fluoride, 5 mg/ml aprotinin, 5 mg/ml leupeptin, and
3 mg/ml pepstatin A). Other cells were lysed with a Triton-lysis buffer (20 mM
HEPES [pH 7.4], 100 mM NaCl, 10 mM b-glycerophosphate, 50 mM NaF, 1%
Triton X-100, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 5 mg/ml apro-
tinin, 5 mg/ml leupeptin, and 3 mg/ml pepstatin A). For immunoprecipitations,
5 mg protein A-Sepharose CL-4B (GE Healthcare) preincubated with a mixture
of 2.5 mg of each rabbit anti-mouse IgG and either a FLAG (Sigma-Aldrich) or
a V5 epitope antibody (Invitrogen). The Sepharose was added to cellular lysates
or supernatants for 12 hr. The Sepharose was sedimented by centrifugation
and washed with PBS containing 0.05% Tween20 (pH 6.5). The proteins
were released by heat treatment in 23 Laemmli buffer and separated by
SDS-PAGE. After transfer to a PVDF membrane (Pall Gelman Laboratory)
proteins were detected by enhanced chemiluminescence (Pierce) using the
respective tag antibody and a horseradish peroxidase-conjugated secondary
antibody (DAKO). Proteins precipitated with IL-6-Sepharose were analyzed
the same way. STAT3 phosphorylation was detected in cellular lysates by
SDS-PAGE and western blotting using a STAT3-pY705 antibody (Cell
Signaling). After stripping of the membrane, total STAT3 was stained with a
STAT3 antibody (Transduction Laboratories). For native gels, the Novex Bis-
Tris gradient gel system (4%–16% polyacrylamide) was used. Gels were run
at 4C. Western blotting of native gels was performed as described in the
manual of the supplier (Invitrogen). YFP fluorescence within native gels was
detected using a Typhoon fluorescence scanner (Amersham).792 Chemistry & Biology 16, 783–794, July 31, 2009 ª2009 ElsevierFlow Cytometry
Cell surface expression of mIL-6Ra-YFP and the corresponding mutants in the
stably transfected HepG2 cells was analyzed by flow cytometry. 2.5 3 106
cells were incubated with a 100-fold diluted mIL-6Ra antibody (anti-CD126;
BD Biosciences) and a phycoerythrin-conjugated IgG-F(ab)2 fragment
(Dianova). Specificity was controlled using an isotype-matched antibody. Cells
(105) were analyzed using 488 nm argon laser light for excitation and a 576 nm
longpass filter for detection.
EMSA
HepG2 cells stably transfected with mIL-6Ra-YFP wild-type or the SGS
mutant were stimulated with different concentrations of mIL-6. Nuclear
extracts were prepared as described previously (Andrews and Faller, 1991).
Protein concentrations were measured using a NanoDrop spectral photometer
(NanoDrop Technologies). A double-stranded mutated sis-inducible element
oligonucleotide derived from the c-fos promotor (m67SIE [Wagner et al.,
1990]: 50-GATCCGGGAGGGATTTACGGGAAATGCTG-30 ) was labeled by
filling in 50-protruding ends with the Klenow enzyme (Roche) using a-[32P]dATP
(Hartmann). Nuclear extracts containing 5 mg protein were incubated with
30,000 cpm of labeled oligonucleotide in gel shift incubation buffer (10 mM
HEPES [pH 7.8], 1 mM EDTA, 5 mM MgCl2, 10% glycerol, 5 mM DTT, 0.7 mM
PMSF, 0.1 mg/ml of poly(dI-dC), and 1 mg/ml BSA) for 10 min at room temper-
ature. The DNA-protein complexes were separated on a 5% polyacrylamide
gel containing 7.5% glycerol in 0.25% TBE (200 mM Tris, 166 mM boric
acid, and 2 mM EDTA, adjusted to pH 8.3) at 250 V. Gels were fixed in a water
solution of 10% methanol and 10% acetic acid for 15 min and dried and auto-
radiographed using a PhosphoScreen (Kodak) and a Typhoon gel imager
(Amersham). Data were analyzed with the program ImageQuant (Molecular
Dynamics).
Reporter Gene Assay
HepG2 cells stably transfected with mIL-6Ra-YFP wild-type or the SGS
mutant were transiently transfected with a firefly luciferase reporter gene
construct under control of the STAT3 inducible rat a2-macroglobulin promoter
(pGL3a2M-215-Luc, based on plasmid pGL3 from Promega) and a control
plasmid for constitutive expression of renilla luciferase (pGL4.70[hRluc]; Prom-
ega). Twelve hours after transfection cells were stimulated for 16 hr with
various concentrations of mIL-6. Cells were lysed and luciferase activity was
measured with the dual luciferase reporter system (Promega) in a 96 well plate
using a luminometer (Berthold).
Proliferation Assay
B9 cells were cultivated in microtest 96 well cell culture plates (Falcon; BD
Biosciences) with a constant amount of mIL-6 (10 pg/ml) in the presence of
mIL-6-RFP or the neutralizing IL-6 antibody (mab406; R&D Systems) at
different concentrations (serial 2-fold dilutions) for 72 hr. Equivalent volumes
of mock vector-transfected cell supernatant or isotype-matched IgG were
used as controls. After 72 hr of incubation, viable cells were quantified using
the Cell Proliferation Kit II (XTT) (Roche).
Confocal Microscopy
Cell surface expression of mIL-6Ra-YFP and the corresponding mutants in the
stably transfected HepG2 cells was analyzed by confocal microscopy of living
cells using a Zeiss LSM 510 Meta confocal laser scanning microscope and
a 633 water-corrected immersion objective with a numerical aperture of
1.2 (C-Apochromat 633/1.2w). Cells were seeded on 30 mm coverslips and
analyzed under cell culture conditions (37C, 5% CO2). The membranes of
the cells were stained with a 0.5% solution of trypan blue. YFP was excited
with laser light of 488 nm and fluorescence was detected using a 505–
550 nm bandpass filter. Trypan blue fluorescence was analyzed with the
Meta detector above 630 nm. The pinhole was adjusted to 1 Airy unit resulting
in optical slices of about 1 mm.
Molecular Modeling
For molecular modeling and graphic representation of protein structures, the
programs WHAT IF (Vriend, 1990) and PyMOL (DeLano Scientific) were
used. The structure of human IL-6Ra (Varghese et al., 2002) (Brookhaven
data bank entry code 1N26) was used as template for the model structure ofLtd All rights reserved
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tions with the GROMOS program library (BIOMOS Biomolecular Software
B.V.). The Swiss-Prot accession numbers for the sequences used in the align-
ment were: mouse, NP_034689; human, BAD97302; pig, BAD97302; rat,
P22273; rhesus monkey, XP_001114404; white-tufted ear marmoset,
ABH03457; chicken, NP_001038140; dog, XP_855105; cattle, XP_583952.
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